A Phase 2 interventional study of Bomedemstat in Essential Thrombocythemia, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 43rd largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2020, is one of 49 in phase 2, and was the 123rd registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
Browse Thrombocythemia, Essential studies →18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Austria and 19 more countries
Ages 18+
Damora Therapeutics · Sites in United States, Australia
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
MPN Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 66 · Phase 3 18
First in 1992; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 45 across the 120 interventional studies, 592 across the 13 observational. Of the 113 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 149 have an industry lead sponsor. The 10 most frequent:
This study is registered under Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Merck & Co., Inc has 5 studies filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
10 of the studies in Thrombocythemia, Essential with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia.
This study investigates the following:
This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and pharmacodynamics of Bomedemstat administered orally once daily in patients with essential thrombocythemia (ET). Patients will be dosed with Bomedemstat for 169 consecutive days in the Initial Treatment Period (ITP). Qualifying patients may continue to receive Bomedemstat in the Additional Treatment Period (ATP).
Safety will be evaluated by clinical assessments of safety parameters i.e., safety laboratory testing, adverse event reporting, physical examination and vital sign assessments. Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden, change in spleen size by palpation and other measures.
To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters and pharmacodynamic markers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bomedemstat administered daily for 169 consecutive days
Drug: Bomedemstat
Oral administration
Also known as: IMG-7289, MK-3543
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.
Time frame: Up to approximately 30 months
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.
Time frame: Up to approximately 28 months
Percentage of Participants With Platelet Count ≤400 k/μL at Day 169
Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to ≤400k/μL in the absence of new thrombolytic events is reported.
Time frame: Up to day 169
| Milestone | Bomedemstat |
|---|---|
| Started | 73 |
| Completed | 64 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lack of efficacy | 1 |
| Milestone | Bomedemstat |
|---|---|
| Started | 63 |
| Completed | 52 |
| Not completed | 11 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Adverse event | 7 |
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 73 |
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 11 |
Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to ≤400k/μL in the absence of new thrombolytic events is reported.
| Percentage of Participants | Bomedemstat |
|---|---|
| Percentage of Participants With Platelet Count ≤400 k/μL at Day 169 | 76.6 (64.3 to 86.2) |
Collected over Up to approximately 30 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bomedemstat | 2/73 (2.7%) | 27/73 (37%) | 72/73 (98.6%) |
| Event | Bomedemstat |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 4/73 |
| PneumoniaInfections and infestations | 3/73 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/73 |
| DiverticulitisInfections and infestations | 2/73 |
| ContusionInjury, poisoning and procedural complications | 2/73 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/73 |
| AnemiaBlood and lymphatic system disorders | 1/73 |
| Atrial fibrillationCardiac disorders | 1/73 |
| Cardiac failureCardiac disorders | 1/73 |
| Abdominal painGastrointestinal disorders | 1/73 |
| Event | Bomedemstat |
|---|---|
| DysgeusiaNervous system disorders | 43/73 |
| ConstipationGastrointestinal disorders | 29/73 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/73 |
| ThrombocytopeniaBlood and lymphatic system disorders | 23/73 |
| FatigueGeneral disorders | 21/73 |
| COVID-19Infections and infestations | 19/73 |
| ContusionInjury, poisoning and procedural complications | 18/73 |
| DiarrhoeaGastrointestinal disorders | 15/73 |
| AnaemiaBlood and lymphatic system disorders | 14/73 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/73 |
| Age, Continuous(Years) | Bomedemstat |
|---|---|
| Mean | 64.8 ± 10.40 |
| Sex: Female, Male(Participants) | Bomedemstat |
|---|---|
| Female | 42 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Bomedemstat |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 71 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Bomedemstat |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 18 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 51 |
| More than one race | 0 |
| Unknown or not reported | 0 |
| Aboriginal | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Mar 2023, 30 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) →